Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) increases tissue glucose uptake and causes vasodilation independent of insulin. We examined the effect of GLP-1 on muscle microvasculature and glucose uptake. After confirming that GLP-1 potently stimulates nitric oxide (NO) synthase (NOS) phosphorylation in endothelial cells, overnight-fasted adult male rats received continuous GLP-1 infusion (30 pmol/kg/min) for 2 h plus or minus NOS inhibition. Muscle microvascular blood volume (MBV), microvascular blood flow velocity (MFV), and microvascular blood flow (MBF) were determined. Additional rats received GLP-1 or saline for 30 min and muscle insulin clearance/uptake was determined. GLP-1 infusion acutely increased muscle MBV (P < 0.04) within 30 min without altering MFV or femoral blood flow. This effect persisted throughout the 120-min infusion period, leading to a greater than twofold increase in muscle MBF (P < 0.02). These changes were paralleled with increases in plasma NO levels, muscle interstitial oxygen saturation, hind leg glucose extraction, and muscle insulin clearance/uptake. NOS inhibition blocked GLP-1–mediated increases in muscle MBV, glucose disposal, NO production, and muscle insulin clearance/uptake. In conclusion, GLP-1 acutely recruits microvasculature and increases basal glucose uptake in muscle via a NO-dependent mechanism. Thus, GLP-1 may afford potential to improve muscle insulin action by expanding microvascular endothelial surface area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 can also enhance the uptake and utilization of glucose in muscle and adipose tissues.207–209”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [207]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 3×
“Incubation of the cells with exendin (9-39) (10 nmol/L), a specific GLP-1 receptor antagonist, completely abolished GLP-1–induced eNOS phosphorylation at Ser(1177), confirming that GLP-1 acted via its receptors (Fig.”
BackgroundRetractedThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 5×
“GLP-1 was given as continuous infusion because of its shorter plasma half-life secondary to rapid degradation by enzyme dipeptidyl peptidase IV (5,31).”
BackgroundMethodInfluentialThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“Activation of the GLP-1 receptors regulates blood glucose concentration by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety (5).”
BackgroundMethodKim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation
Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segawa, K., Furukawa, S., Tochino, Y., Komuro, R., Matsuda, M., et al. (2007) · Diabetes · doi:10.2337/db06-0911 · Cited by 1,257
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Ye, J., Gao, Z., Yin, J., & He, Q. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00435.2007 · Cited by 840 · cited 2×
“Incubation of the cells with exendin (9-39) (10 nmol/L), a specific GLP-1 receptor antagonist, completely abolished GLP-1–induced eNOS phosphorylation at Ser(1177), confirming that GLP-1 acted via its receptors (Fig.”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 6×
“1): In protocol 1, rats received an intravenous infusion of saline (control) or GLP-1 (7-36) amide (30 pmol/kg/min; Bachem Americas, Inc.”
BackgroundMethodInfluentialEmerging role of adipose tissue hypoxia in obesity and insulin resistance
Ye, J. (2009) · International Journal of Obesity · doi:10.1038/ijo.2008.229 · Cited by 543
Cited by
Items 201–201 of 201
Sultan, L. R., Morgan, T. A., McGinn, D. E., Darge, K., Gendler, L., Nguyen, J., Brennan, E., Brother, J. A., Xiao, R., Falk, M. J., et al. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261486870
“22 Detecting subtle microvascular changes, especially under exercise or stress, requires imaging modalities capable of capturing dynamic microcirculatory alterations to facilitate a more comprehensive evaluation and characterization of regional muscle perfusion and pathologic alteration.”
Metadata
- Authors
- Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z.
- Affiliations
- University of Virginia Health System (US)
- Shandong University (CN)
- Central South University (CN)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Liu, Zhenqi
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-03-14
- Volume
- 61
- Issue
- 4
- Pages
- 888-896
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3314347
- OpenAlex
- W2130375560
- Cited by
- 194
- References
- 47
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 9 · 2023: 9 · 2022: 11 · 2021: 17 · 2020: 13 · 2019: 9 · 2018: 17 · 2017: 8 · 2016: 13 · 2015: 15 · 2014: 24 · 2013: 23 · 2012: 6
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association (1-11-CR-30, 9-09-NOVO-11)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL094722)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- glucagon-like peptide-1, nitric oxide, nitric oxide synthase, muscle microvasculature, muscle glucose uptake, microvascular blood flow, endothelial cells, insulin clearance, insulin resistance, vasodilation, glucose extraction
- MeSH terms
- Animals, Aorta, Cattle, Cells, Cultured, Drug Administration Schedule, Gene Expression Regulation, Glucose, Hormones, Insulin, Male, Nitric Oxide, Somatostatin, Rats, Sprague-Dawley, Cyclic AMP-Dependent Protein Kinases, Muscle, Skeletal, NG-Nitroarginine Methyl Ester, Endothelial Cells, Proto-Oncogene Proteins c-akt, Rats, Glucagon-Like Peptide 1, Nitric Oxide Synthase Type III, Microvessels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.